GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » EV-to-EBIT

Cadrenal Therapeutics (Cadrenal Therapeutics) EV-to-EBIT : -0.03 (As of May. 25, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cadrenal Therapeutics's Enterprise Value is $0.16 Mil. Cadrenal Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.85 Mil. Therefore, Cadrenal Therapeutics's EV-to-EBIT for today is -0.03.

The historical rank and industry rank for Cadrenal Therapeutics's EV-to-EBIT or its related term are showing as below:

CVKD' s EV-to-EBIT Range Over the Past 10 Years
Min: -69.84   Med: 0   Max: 0.51
Current: -0.03

During the past 2 years, the highest EV-to-EBIT of Cadrenal Therapeutics was 0.51. The lowest was -69.84. And the median was 0.00.

CVKD's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs CVKD: -0.03

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cadrenal Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $3.21 Mil. Cadrenal Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.85 Mil. Cadrenal Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -150.77%.


Cadrenal Therapeutics EV-to-EBIT Historical Data

The historical data trend for Cadrenal Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics EV-to-EBIT Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23
EV-to-EBIT
- -0.15

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only -1.89 -2.03 0.03 -0.15 -0.66

Competitive Comparison of Cadrenal Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Cadrenal Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadrenal Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cadrenal Therapeutics's EV-to-EBIT falls into.



Cadrenal Therapeutics EV-to-EBIT Calculation

Cadrenal Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.156/-4.846
=-0.03

Cadrenal Therapeutics's current Enterprise Value is $0.16 Mil.
Cadrenal Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cadrenal Therapeutics  (NAS:CVKD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cadrenal Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-4.846/3.214185
=-150.77 %

Cadrenal Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $3.21 Mil.
Cadrenal Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cadrenal Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadrenal Therapeutics (Cadrenal Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029